Opthea Limited (OPT)
- Previous Close
3.6400 - Open
3.5000 - Bid --
- Ask --
- Day's Range
3.4000 - 3.5000 - 52 Week Range
1.6000 - 4.4200 - Volume
2,995 - Avg. Volume
21,269 - Market Cap (intraday)
281.693M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.17
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
opthea.comRecent News: OPT
Performance Overview: OPT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPT
Valuation Measures
Market Cap
270.21M
Enterprise Value
113.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.93k
Price/Book (mrq)
--
Enterprise Value/Revenue
967.36
Enterprise Value/EBITDA
-0.76
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-64.33%
Return on Equity (ttm)
-3,383.08%
Revenue (ttm)
390.44k
Net Income Avi to Common (ttm)
-161.61M
Diluted EPS (ttm)
-2.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
157.07M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-85.32M